Company Overview

It’s Time to Revolutionize Medicine Again

Shionogi Inc. is the U.S. subsidiary of Shionogi & Co., Ltd., a 139-year-old global pharmaceutical company with headquarters in Osaka, Japan. In the U.S., Shionogi Inc. leverages our science-based heritage to develop and commercialize pharmaceutical products to treat unmet medical needs in our core areas of infectious diseases and pain, as well as other areas of high medical need, including chronic liver disease.

More than 23,000 men, women, and children in the U.S. die every year from antibiotic-resistant infections1 while over 4,000 Americans perish from influenza2. In addition, over 100 million suffer from chronic pain3 and 3.9 million adults in the U.S. are diagnosed with liver disease4. Shionogi's mission is to supply the best possible medicines to protect the health and well-being of the patients we serve.

With over 50 years of anti-infective research experience, Shionogi has helped to revolutionize the development of anti-bacterial and anti-viral treatments. As bacteria, pathogens, and other viruses adapt to resist existing treatments—causing millions of untreatable infections around the world—Shionogi is pursuing the development of novel treatments to combat this evolving threat.

Shionogi, both itself and through innovative alliances, is also pursuing the development of new treatments in other areas of high medical need, including inflammatory pain, neuropathic pain, Alzheimer’s disease, and ADHD.

At Shionogi Inc., we’re intensely focused on developing and commercializing the scientific breakthroughs emerging from our research laboratories in Japan as well as discoveries of our strategic alliance partners. We couple our innovative discovery base with capabilities to advance drug candidates rapidly from lab to clinic to patient, forming, where appropriate, bold new partnerships to accelerate and amplify the availability of these new medications to patients around the world.

139 Years of Entrepreneurship

In 1878, Gisaburo Shiono, Sr. founded the company that became Shionogi & Co., Ltd. Still located on the original site in Osaka, Japan, today’s Shionogi retains its entrepreneurial spirit while having the resources of a fully integrated pharmaceutical company serving patients worldwide. Our research scientists have discovered therapeutics including naldemedine, rosuvastatin, and dolutegravir, and are currently working on many more potential future products.

In 2008, Shionogi acquired Sciele Pharma, Inc., a specialty pharmaceutical company based in Atlanta, Georgia, and in 2011, merged it with Shionogi’s small existing development organization in New Jersey. The resulting company became Shionogi Inc., which has the mandate to bring Shionogi innovation to U.S. patients. In 2017, Shionogi Inc. gained approval of Symproic®, the first medicine both discovered and globally developed by Shionogi.

Shionogi Inc. now has a development organization capable of conducting multiple simultaneous late-stage clinical programs and submitting new drug application (NDA) filings worldwide, and we are now establishing the commercial capabilities to effectively bring these medicines to the appropriate patients.

References

  1. www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf
  2. https://www.cdc.gov/nchs/fastats/flu.htm
  3. Institute of Medicine Report from the Committee on Advancing Pain Research, Care, and Education: Relieving Pain in America, A Blueprint for Transforming Prevention, Care, Education and Research. The National Academies Press, 2011. http://books.nap.edu/openbook.php?record_id=13172&page=1
  4. https://www.cdc.gov/nchs/fastats/liver-disease.htm